Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Intervalo de año de publicación
1.
Nanoscale ; 13(1): 218-232, 2021 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-33326529

RESUMEN

Extracellular vesicles (EVs), especially from stem/stromal cells (SCs), represent a cell-free alternative in regenerative medicine holding promises to promote tissue healing while providing safety and logistic advantages in comparison to cellular counterparts. Herein, we hypothesize that SC EVs, administered locally in a thermoresponsive gel, is a therapeutic strategy for managing post-surgical colo-cutaneous fistulas. This disease is a neglected and challenging condition associated to low remission rates and high refractoriness. Herein, EVs from a murine SC line were produced by a high-yield scalable method in bioreactors. The post-surgical intestinal fistula model was induced via a surgical cecostomy communicating the cecum and the skin in Wistar rats. Animals were treated just after cecostomy with PBS, thermoresponsive Pluronic F-127 hydrogel alone or containing SC EVs. A PET-monitored biodistribution investigation of SC EVs labelled with 89Zr was performed. Fistula external orifice and output assessment, probe-based confocal laser endomicroscopy, MRI and histology were carried out for therapy follow-up. The relevance of percutaneous EV administration embedded in the hydrogel vehicle was indicated by the PET-biodistribution study. Local administration of SC EVs in the hydrogel reduced colo-cutaneous fistula diameter, output, fibrosis and inflammation while increasing the density of neo-vessels when compared to the PBS and gel groups. This multi-modal investigation pointed-out the therapeutic potential of SC EVs administered locally and in a thermoresponsive hydrogel for the management of challenging post-surgical colon fistulas in a minimally-invasive cell-free strategy.


Asunto(s)
Fístula Cutánea , Vesículas Extracelulares , Células Madre Mesenquimatosas , Animales , Colon , Fístula Cutánea/metabolismo , Vesículas Extracelulares/metabolismo , Hidrogeles/metabolismo , Ratones , Ratas , Ratas Wistar , Células Madre , Distribución Tisular
2.
Head Neck Pathol ; 14(2): 341-352, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31250279

RESUMEN

Pharyngocutaneous fistulae (PCF) are one of the most common complications after laryngectomy. Predisposing risk factors have been studied, yet knowledge to determine which patients are prone to developing a fistula remains scarce. This study aims to establish prognostic parameters to identify individual patients at risk for PCF development. As PCF and inflammation seem to be interwoven, this work focuses on markers able to detect an inflammatory response. We retrospectively analyzed all patients who had undergone a laryngectomy at our clinic in the years 2007 to 2017 (n = 182). Immunohistochemical expression of bradykinin type 1 and 2 receptor and vascular endothelial growth factor receptor 2 was studied in all available tumor samples. Additionally, the clinical inflammation parameters 'body temperature', 'pain', 'c-reactive protein (CRP)', and 'leucocytes' were postoperatively tracked in all patients. The times between fistula diagnosis, therapeutic approach, and hospital discharge were recorded. We found a strong correlation between inflammation and the formation of a fistula. High bradykinin 1 receptor expression in the tumor samples correlated with postoperative PCF development. Persistently elevated CRP and leukocyte levels beyond the 6th postoperative day were also risk factors. A decreased time lapse between PCF diagnosis and surgical revision clearly correlated with a shorter hospital stay. In this study, we identified a bradykinin 1 receptor positive patient group at high risk for development of PCF. We recommend close monitoring for fistula formation in these patients to ensure timely intervention.


Asunto(s)
Fístula Cutánea/etiología , Fístula/etiología , Inflamación/metabolismo , Laringectomía/efectos adversos , Enfermedades Faríngeas/etiología , Anciano , Biomarcadores/análisis , Proteína C-Reactiva/metabolismo , Fístula Cutánea/metabolismo , Femenino , Fístula/metabolismo , Humanos , Inflamación/etiología , Enfermedades de la Laringe/cirugía , Masculino , Persona de Mediana Edad , Enfermedades Faríngeas/metabolismo , Pronóstico , Receptor de Bradiquinina B1/metabolismo , Estudios Retrospectivos , Factores de Riesgo
3.
Arch. esp. urol. (Ed. impr.) ; 68(7): 633-636, sept. 2015. ilus
Artículo en Español | IBECS | ID: ibc-144576

RESUMEN

OBJETIVO: Presentar el manejo terapéutico de complicaciones graves relacionadas con la extravasación de mitomicina postoperatoria. MÉTODOS: Descripción de los casos clínicos, el manejo médico y quirúrgico, y los resultados anatomopatológicos de las piezas quirúrgicas. RESULTADOS: Presentamos dos casos de pacientes con fuga extravesical de mitomicina tras su instilación en el postoperatorio. No se evidenció perforación de vejiga durante la cirugía del tumor. En ambos casos fue necesaria la realización de cistectomía radical. CONCLUSIONES: El uso de mitomicina en el postoperatorio puede tener consecuencias no deseables. Deben conocerse los problemas que pueden derivar de su administración e individualizar cada caso antes de administrar este quimioterápico


OBJECTIVE: To present the therapeutic management of severe complications related to postoperative mitomycin extravasation. METHODS: Description of clinical cases, medical and surgical management and pathologic results of surgical specimens. RESULTS: We report two cases of patients with extravesical mitomycin leakage after postoperative instillation. No bladder perforation was evident during tumor surgery. In both cases radical cystectomy was required. CONCLUSIONS: Postoperative mitomycin instillation may have undesirable consequences. The possible problems derived from its administration must be known, and each case must be individualized before administering this chemotherapy


Asunto(s)
Adulto , Humanos , Masculino , Extravasación de Materiales Terapéuticos y Diagnósticos/complicaciones , Mitomicina/administración & dosificación , Mitomicina , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/radioterapia , Cistectomía/métodos , Cistectomía/enfermería , Terapéutica/métodos , Fístula Cutánea/sangre , Extravasación de Materiales Terapéuticos y Diagnósticos/enfermería , Extravasación de Materiales Terapéuticos y Diagnósticos/cirugía , Mitomicina/clasificación , Mitomicina/orina , Cistectomía/instrumentación , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/terapia , Cistectomía/normas , Terapéutica/normas , Fístula Cutánea/metabolismo
4.
Khirurgiia (Mosk) ; (8): 62-6, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-25327679

RESUMEN

Evaluation of the efficacy of sekretoliticeskoj therapy with synthetic analogue of somatostatin, a short-acting oktreotid (group 1) and extended oktreotid-depo (group 2) in 24 patients with external pancreatic fistulas after destructive pancreatitis. Results of clinical studies have shown that against the backdrop of an analogue of somatostatin-depo true healing and purulent-necrotic pancreatic external fistula occurs in less time: average 19 ± 1.8, and 16.2 ± 1.2 day observations, respectively.


Asunto(s)
Antibacterianos/administración & dosificación , Fístula Cutánea/tratamiento farmacológico , Octreótido/administración & dosificación , Páncreas Exocrino/efectos de los fármacos , Fístula Pancreática/tratamiento farmacológico , Adulto , Amilasas/metabolismo , Investigación sobre la Eficacia Comparativa , Fístula Cutánea/etiología , Fístula Cutánea/metabolismo , Formas de Dosificación , Quimioterapia Combinada , Femenino , Fármacos Gastrointestinales/administración & dosificación , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Páncreas Exocrino/metabolismo , Fístula Pancreática/etiología , Fístula Pancreática/metabolismo , Pancreatitis/complicaciones , Resultado del Tratamiento , Cicatrización de Heridas/efectos de los fármacos
5.
Br J Surg ; 93(9): 1045-55, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16804873

RESUMEN

BACKGROUND: The management of enterocutaneous fistula is challenging, with significant associated morbidity and mortality. This article reviews treatment, with emphasis on the provision and optimal route of nutritional support. METHODS: Relevant articles were identified using Medline searches. Secondary articles were identified from the reference lists of key papers. RESULTS AND CONCLUSION: Management of enterocutaneous fistula should initially concentrate on correction of fluid and electrolyte imbalances, drainage of collections, treatment of sepsis and control of fistula output. The routine use of somatostatin infusion and somatostatin analogues remains controversial; although there are data suggesting reduced time to fistula closure, there is little evidence of increased probability of spontaneous closure. Malnutrition is common and adequate nutritional provision is essential, enteral where possible, although supplemental parenteral nutrition is often required for high-output small bowel fistulas. The role of immunonutrition is unknown. Surgical repair should be attempted when spontaneous fistula closure does not occur, but it should be delayed for at least 3 months.


Asunto(s)
Fístula Cutánea/cirugía , Nutrición Enteral/métodos , Fístula Intestinal/cirugía , Desnutrición/prevención & control , Nutrición Parenteral/métodos , Fístula Cutánea/complicaciones , Fístula Cutánea/metabolismo , Drenaje/métodos , Humanos , Fístula Intestinal/complicaciones , Fístula Intestinal/metabolismo , Desnutrición/etiología , Equilibrio Hidroelectrolítico
6.
Am J Gastroenterol ; 98(5): 1101-6, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12809834

RESUMEN

OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) plays a key role in the inflammatory response and pathogenesis of Crohn's disease (CD). TNF-alpha -308A polymorphism within the TNF-alpha gene promoter has been associated with enhanced TNF-alpha production in vitro. The aim of this study was to investigate the effect of TNF-alpha promoter polymorphism at -308 on the susceptibility and phenotypic expression of fistulizing CD. METHODS: The distribution of -308 TNF-alpha genotypes was analyzed in 50 patients with fistulizing CD and 100 healthy matched controls. TNF-alpha, interleukin-1beta, and interleukin-6 serum levels were measured by ELISA. Serum amyloid-A, C-reactive protein, alpha1-antitrypsin, alpha1-acid glycoprotein, and haptoglobin were measured by nephelometry. RESULTS: No significant differences were found in the allele frequencies of the polymorphism between patients and controls. However, compared with -308GG patients, those carrying -308AG had a significant increase of serum levels of TNF-alpha (58 +/- 79 vs 8 +/- 19 pg/ml, p < 0.001), interleukin-1beta (36 +/- 45 vs 16 +/- 20 pg/ml, p = 0.048), and acute phase proteins (APPs). -308A carriers had also a higher frequency of arthritis (66% vs 26%, p = 0.039). The logistic regression model showed that the patients carrying -308A polymorphism had a relative risk for developing arthritis of 5.45 (95% CI = 1.1-25.6). No other clinical or analytical findings were predictive for the risk of development of arthritis. CONCLUSIONS: TNF-alpha -308A polymorphism is associated with enhanced TNF-alpha production, more intense inflammatory activity, and an increased risk for arthritis susceptibility in CD patients with fistulizing disease.


Asunto(s)
Enfermedad de Crohn/genética , Fístula Cutánea/genética , Polimorfismo Genético , Fístula Rectal/genética , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/genética , Proteínas de Fase Aguda/análisis , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Enfermedad de Crohn/metabolismo , Fístula Cutánea/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Regiones Promotoras Genéticas , Fístula Rectal/metabolismo
7.
World J Gastroenterol ; 8(6): 1149-52, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12439943

RESUMEN

AIM: To investigate the sequential changes of body composition in the metabolic response that occurred in a group of patients with enterocutaneous fistula after admission to the hospital. METHODS: Sixty-one patients with enterocutaneous fistula admitted to our hospital had measurements of body composition by multiple-frequency bioelectrical impedance analysis after admission and 5, 10 days later. Sequential measurements of plasma constitutive proteins were also made. RESULTS: The body weight, fat-free mass, body mass index, and body cell mass were initially well below the normal range, especially the body mass index and body cell mass. And all the data gradually moved up over the 10-day study period, only a highly significant difference was found in body cell mass. Once the patients received nutrition supplement, ECW began to return to normal range slowly as well as ICW and TBW began to rise up, and ECW/TBW significantly declined to near normal level by day 10 in either male or female patients. There was a reprioritization of plasma constitutive protein synthesis that was obligatory and independent of changes in FFM. CONCLUSION: Serial measurements can quantify the disturbance of body composition in enterocutaneous fistula patients. The early nutritional intervention rapidly ameliorates the abnormal distribution of body water while the state-of-the-art surgical management prevents the further deterioration in cellular composition.


Asunto(s)
Fístula Cutánea/metabolismo , Fístula del Sistema Digestivo/metabolismo , Adulto , Proteínas Sanguíneas/metabolismo , Composición Corporal , Índice de Masa Corporal , Agua Corporal/metabolismo , Fístula Cutánea/patología , Fístula Cutánea/terapia , Fístula del Sistema Digestivo/patología , Fístula del Sistema Digestivo/terapia , Impedancia Eléctrica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo
8.
Br J Dermatol ; 141(2): 231-9, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10468793

RESUMEN

The draining sinus is a late complication of several forms of severe acne, leading to extensive, periodically inflamed lesions that are undermined by a system of fistulas, supposed to be of follicular origin. We investigated the expression of various cytokeratins (CKs) and desmosomal proteins in the draining sinus of acne inversa (hidradenitis suppurativa) using monoclonal antibodies in immunohistochemistry on paraffin-embedded sections. We were able to define three different phenotypes of stratified squamous epithelia covering the sinus tracts. Type I epithelium was cornifying and characterized by the presence of CK 10, desmogleins 1-3 and desmocollins 1-3 in an epidermis-like pattern. Type II epithelium was non-cornifying, negative for CK 10 and positive for CK 13. It was negative for desmocollin 1 but strongly immunopositive for desmoglein 1 suprabasally and for desmoglein 2 in the basal cells. Type III epithelium was non-cornifying and strongly inflamed. It was marked by the presence of CK 7, CK 19 and desmoglein 2 and the absence of CK 10, desmoglein 1 and desmocollin 1. In both type II and III epithelium, desmoglein 3, desmocollin 2 and desmocollin 3 showed an inverted staining pattern as compared with normal epidermis and type I epithelium. Desmoglein 2 and CK 5/14 always remained restricted to the basal cell layer. Antibodies against CK 6 and CK 13/15/16 were immunopositive in all three phenotypes and CK 17 was predominantly immunolocalized to suprabasal layers of type II and III epithelium. The three phenotypes are characterized as pathological stratified squamous epithelia reflecting the dynamic process of inflammation, proliferation and stratification taking place in acne inversa.


Asunto(s)
Fístula Cutánea/patología , Hidradenitis Supurativa/patología , Anticuerpos Monoclonales/metabolismo , Diferenciación Celular , Fístula Cutánea/metabolismo , Proteínas del Citoesqueleto/metabolismo , Desmocolinas , Desmogleína 1 , Desmogleína 2 , Desmogleína 3 , Desmogleínas , Desmoplaquinas , Epitelio/metabolismo , Hidradenitis Supurativa/metabolismo , Humanos , Inmunohistoquímica , Queratinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...